International Urology and Nephrology

, Volume 44, Issue 6, pp 1841–1845

Troponin I as a prognostic marker of cardiac events in asymptomatic hemodialysis patients using a sensitive troponin I assay

  • Meghana R. Gaiki
  • Maria V. DeVita
  • Michael F. Michelis
  • Georgia Panagopoulos
  • Jordan L. Rosenstock
Nephrology – Original Paper

Abstract

Elevated troponin T is known to be a prognostic marker for long-term cardiac events and mortality in asymptomatic end-stage renal disease patients. There are conflicting data in this regard with respect to troponin I (TnI). We recently showed a high incidence of elevated TnI levels in asymptomatic hemodialysis (HD) patients using a new generation sensitive TnI assay. The aim of this pilot study was to explore the prognostic value of TnI, as measured with this new assay, as a marker for outcomes in HD patients over a 2-year follow-up period. Fifty-one asymptomatic HD patients were enrolled, and pre-dialysis TnI levels were checked once monthly over 3 consecutive months. Patients were considered to be in the TnI positive group if TnI level on any of the three draws was ≥0.035 ng/ml. All patients were followed for a period of 2 years. The primary end points were acute coronary syndrome, coronary revascularization, sudden death, or cardiac arrest. The secondary end point was all-cause mortality. Elevated TnI levels were found in 51% (26/51) of patients in our cohort. One TnI positive patient was subsequently lost to follow up. There were 6 cardiac events over 2 years, all of which were in the troponin positive group (6/25 or 24%). The presence of a positive TnI at baseline was significantly associated with future cardiac events (p = 0.022). A prior history of coronary artery disease (CAD) was also significantly related to future cardiac events (p = 0.010). No patient with negative TnI at baseline developed a cardiac event, while 45.5% of those with both a positive TnI and a history of CAD had an event. Fourteen deaths occurred over 2 years, 8 in TnI positive and 6 in the negative group. All-cause mortality was not associated with elevated TnI levels at baseline. We found a significant association between positive TnI and subsequent cardiac events in asymptomatic HD patients followed for 2 years. TnI levels, as measured with a sensitive assay, may be useful in assessing cardiac risk in asymptomatic HD patients. This needs further confirmation in a larger cohort.

Keywords

Troponin I High sensitive assay Prognostic marker End-stage dialysis 

References

  1. 1.
    Apple FS, Murakami MAM, Pearce LA, Herzog CA (2002) Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 106:2941–2945PubMedCrossRefGoogle Scholar
  2. 2.
    Wang AYM and Lai KN (2008) Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 19:1643–1652CrossRefGoogle Scholar
  3. 3.
    McLaurin MD, Apple FS, Voss EM, Herzog CA, Sharkey SW (1997) Cardiac, troponin I, cardiac troponin T and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle. Clin Chem 43:976–982PubMedGoogle Scholar
  4. 4.
    Kumar N, Michelis MF, DeVita MV, Panagopoulos G, Rosenstock JL (2010) Troponin I levels in asymptomatic patients on hemodialysis using a high-sensitivity assay. Nephrol Dial Transplant 26(2):665–670PubMedCrossRefGoogle Scholar
  5. 5.
    Troyanov S, Ly QH, Schampaert E, Ammann H, Laumière G, Madore F, Quèrin S (2005) Diagnostic specificity and prognostic value of cardiac troponins in asymptomatic chronic haemodialysis patients: a 3 year prospective study. Heart 91:1227–1228PubMedCrossRefGoogle Scholar
  6. 6.
    Apple FS, Murakami MAM, Pearce LA, Herzog CA (2004) Multi-biomarker risk stratification of n-terminal pro–b-type natriuretic peptide, high sensitivity c-reactive protein, and cardiac troponin t and in end-stage renal disease for all-cause death. Clin Chem 50(12):2279–2285PubMedCrossRefGoogle Scholar
  7. 7.
    Roberts MA, Fernando D, Macmillan N, Proimos G, Bach LA, Power DA, Ratnaike S, Ierino FL (2004) Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. Clin Nephrol 61(1):40–46PubMedGoogle Scholar
  8. 8.
    Iliou MC, Fumeron C, Benoit MO, Tuppin P, Calonge VM, Moatti N, Buisson C, Jacquot C (2003) Prognostic value of cardiac markers in ESRD: chronic hemodialysis and new cardiac markers evaluation (chance) study. Am J Kidney Dis 42:513–523PubMedCrossRefGoogle Scholar
  9. 9.
    Ishii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y, Ishikawa T, Kurokawa H, Hirano T, Kondo T, Nagamura Y, Ezaki K, Hishida H (2001) Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta 312(1–2):69–79PubMedCrossRefGoogle Scholar
  10. 10.
    Khan IA, Wattanasuwan N, Mehta NJ, Tun A, Singh N, Singh HK, Vasavada BC, Sacchi TJ (2001) Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two-year outcome analysis. J Am Coll Cardiol 38(4):999–1001CrossRefGoogle Scholar
  11. 11.
    Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A (2005) Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 112(20):3088–3096PubMedCrossRefGoogle Scholar
  12. 12.
    Melloni C, Alexander KP, Milford-Beland S, Newby LK, Szczech LA, Pollack CV, Kirk JD, Christenson RH, Harrington RA, Gibler WB, Ohman EM, Peterson ED, Roe MT (2008) Crusade investigators. Prognostic value of troponins in patients with non-ST-segment elevation acute coronary syndromes and chronic kidney disease. Clin Cardiol 31(3):125–129PubMedCrossRefGoogle Scholar
  13. 13.
    Solomon S, Zelenkofske S, McMurray J et al (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352:2581–2588PubMedCrossRefGoogle Scholar
  14. 14.
    Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S, Warnholtz A, Fröhlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB, Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ, Münzel TF, Blankenberg S (2009) Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 361:868–877PubMedCrossRefGoogle Scholar
  15. 15.
    Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C (2009) Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 361:858–867PubMedCrossRefGoogle Scholar
  16. 16.
    Afsar B, Elsurer R, Akgul A, Sezer S, Ozdemir FN (2009) Factors related to silent myocardial damage in hemodialysis patients. Ren Fail 31:933–941PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, B.V. 2012

Authors and Affiliations

  • Meghana R. Gaiki
    • 1
  • Maria V. DeVita
    • 1
  • Michael F. Michelis
    • 1
  • Georgia Panagopoulos
    • 1
  • Jordan L. Rosenstock
    • 1
    • 2
  1. 1.Division of Nephrology, Department of MedicineLenox Hill HospitalNew YorkUSA
  2. 2.New YorkUSA

Personalised recommendations